These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32856212)

  • 1. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
    Suarez-Almazor ME; Pundole X; Abdel-Wahab N; Johnson DB; Gupta D; Glezerman I; Cooksley T; Anderson R; Blidner A; Choi J; Dougan M; Ginex P; Girotra M; Shannon VR; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6159-6173. PubMed ID: 32856212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
    Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
    Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
    Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
    Choi J; Anderson R; Blidner A; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Lacouture ME
    Support Care Cancer; 2020 Dec; 28(12):6119-6128. PubMed ID: 32856211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum and impact of checkpoint inhibitor-induced irAEs.
    Cappelli LC; Bingham CO
    Nat Rev Rheumatol; 2021 Feb; 17(2):69-70. PubMed ID: 33235330
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of immune checkpoint inhibitor-related rheumatic adverse events.
    Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events of checkpoint inhibitors.
    Nat Rev Dis Primers; 2020 May; 6(1):39. PubMed ID: 32382085
    [No Abstract]   [Full Text] [Related]  

  • 11. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicities associated with checkpoint inhibitors-an overview.
    Spiers L; Coupe N; Payne M
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
    Kostine M; Truchetet ME; Schaeverbeke T
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
    Ghosh N; Tirpack A; Chan KK; Bass AR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
    Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
    Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.
    Reid PD; Cifu AS; Bass AR
    JAMA; 2021 Feb; 325(5):482-483. PubMed ID: 33528524
    [No Abstract]   [Full Text] [Related]  

  • 17. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events of checkpoint inhibitors.
    Ramos-Casals M; Brahmer JR; Callahan MK; Flores-Chávez A; Keegan N; Khamashta MA; Lambotte O; Mariette X; Prat A; Suárez-Almazor ME
    Nat Rev Dis Primers; 2020 May; 6(1):38. PubMed ID: 32382051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    König D; Läubli H
    Pharmacology; 2021; 106(3-4):123-136. PubMed ID: 32721966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
    Baik AH; Tsai KK; Oh DY; Aras MA
    Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.